BACKGROUND: This study (NCT00383123) compared the immunogenicity and safety of 2 trivalent inactivated influenza vaccines: Fluarix [GlaxoSmithKline (study vaccine)] and Fluzone [Sanofi Pasteur (control vaccine)] in children 6 months to <18 years. METHODS: Children, stratified by age and randomized, received either study (N = 2115) or control vaccine (N = 1210) at day 0 (and day 28 for previously unvaccinated children younger than 9 years). Children 6 months to <5 years comprised the according-to-protocol (ATP) cohort for immunogenicity, whereas the reactogenicity/safety group included all children 6 months to <18 years. The study aimed to demonstrate immunologic noninferiority of study vaccine versus control vaccine. RESULTS: For children 6 months to <5 years, the predefined noninferiority criteria were not reached, mainly due to the differences in immune response in children 6 months to <3 years with no influenza vaccination history. All reactogenicity/safety endpoints were within the same range in both vaccine groups. CONCLUSIONS: The study vaccine demonstrated a good safety and reactogenicity profile; however, it did not meet the predefined noninferiority criteria in children 6 months to <5 years. The study vaccine was as immunogenic as the control vaccine in children aged 3 to <5 years.
RCT Entities:
BACKGROUND: This study (NCT00383123) compared the immunogenicity and safety of 2 trivalent inactivated influenza vaccines: Fluarix [GlaxoSmithKline (study vaccine)] and Fluzone [Sanofi Pasteur (control vaccine)] in children 6 months to <18 years. METHODS:Children, stratified by age and randomized, received either study (N = 2115) or control vaccine (N = 1210) at day 0 (and day 28 for previously unvaccinated children younger than 9 years). Children 6 months to <5 years comprised the according-to-protocol (ATP) cohort for immunogenicity, whereas the reactogenicity/safety group included all children 6 months to <18 years. The study aimed to demonstrate immunologic noninferiority of study vaccine versus control vaccine. RESULTS: For children 6 months to <5 years, the predefined noninferiority criteria were not reached, mainly due to the differences in immune response in children 6 months to <3 years with no influenza vaccination history. All reactogenicity/safety endpoints were within the same range in both vaccine groups. CONCLUSIONS: The study vaccine demonstrated a good safety and reactogenicity profile; however, it did not meet the predefined noninferiority criteria in children 6 months to <5 years. The study vaccine was as immunogenic as the control vaccine in children aged 3 to <5 years.
Authors: John F Alcorn; Raghunandan Avula; Anish B Chakka; William E Schwarzmann; Mary Patricia Nowalk; Chyongchiou Jeng Lin; Marianna A Ortiz; William T Horne; Uma R Chandran; Jennifer P Nagg; Richard K Zimmerman; Kelly S Cole; Krissy K Moehling; Judith M Martin Journal: Hum Vaccin Immunother Date: 2020-04-16 Impact factor: 3.452
Authors: Robert B Couch; Robert L Atmar; Wendy A Keitel; John M Quarles; Janet Wells; Nancy Arden; Diane Niño Journal: Vaccine Date: 2012-10-26 Impact factor: 3.641
Authors: P K Armstrong; G K Dowse; P V Effler; D Carcione; C C Blyth; P C Richmond; G C Geelhoed; F Mascaro; M Scully; T S Weeramanthri Journal: BMJ Open Date: 2011-05-30 Impact factor: 2.692
Authors: Varsha K Jain; Joseph B Domachowske; Long Wang; Opokua Ofori-Anyinam; Miguel A Rodríguez-Weber; Michael L Leonardi; Nicola P Klein; Gary Schlichter; Robert Jeanfreau; Byron L Haney; Laurence Chu; Jo-Ann S Harris; Kwabena O Sarpong; Amanda C Micucio; Jyoti Soni; Vijayalakshmi Chandrasekaran; Ping Li; Bruce L Innis Journal: J Pediatric Infect Dis Soc Date: 2017-03-01 Impact factor: 3.164
Authors: Noris Pavia-Ruz; Miguel Angel Rodriguez Weber; Yu-Lung Lau; E Anthony S Nelson; Angkool Kerdpanich; Li-Min Huang; Peter Silas; Paul Qaqundah; Mark Blatter; Robert Jeanfreau; Paul Lei; Varsha Jain; Mohamed El Idrissi; Yang Feng; Bruce Innis; Mathieu Peeters; Jeanne-Marie Devaster Journal: Hum Vaccin Immunother Date: 2013-06-19 Impact factor: 3.452